Citations

Mayo Clinic

Showing 10 of 108537 citations.

Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline
Demay, Marie B. , Diab, Dima L., Kiely, Máiréad , Lips, Paul , Powers, Shelley, Tayek, John A. , Walsh, Judith M. E. , Pittas, Anastassios G. , Bikle, Daniel D. , Lazaretti‐Castro, Marise , Mitchell, Deborah M. , Murad, M. Hassan , Powers, Shelley, Rao, Sudhaker D. , Scragg, Robert K.R. , Valent, Amy Miyoshi , McCartney, Christopher R.

The Journal of Clinical Endocrinology & Metabolism | April 25, 2024 | Volume: 109 | Issue: 8 | Pages: 1907-1947

10.1210/clinem/dgae290 | PMID 38828931 Get It

Abstract Background Numerous studies demonstrate associations between serum concentrations of 25-hydroxyvitamin D (25[OH]D) and a variety of common disorders, including musculoskeletal, metabolic, cardiovascular, malignant, autoimmune, and infectious diseases. Although a causal link between serum 25(OH)D concentrations and many disorders has not been clearly established, these associations have led to widespread supplementation with vitamin D and increased laboratory testing for 25(OH)D in the general population. The benefit-risk ratio of this increase in vitamin D use is not clear, and the optimal vitamin D intake and the role of testing for 25(OH)D for disease prevention remain uncertain. Objective To develop clinical guidelines for the use of vitamin D (cholecalciferol [vitamin D3] or ergocalciferol [vitamin D2]) to lower the risk of disease in individuals without established indications for vitamin D treatment or 25(OH)D testing. Methods A multidisciplinary panel of clinical experts, along with experts in guideline methodology and systematic literature review, identified and prioritized 14 clinically relevant questions related to the use of vitamin D and 25(OH)D testing to lower the risk of disease. The panel prioritized randomized placebo-controlled trials in general populations (without an established indication for vitamin D treatment or 25[OH]D testing), evaluating the effects of empiric vitamin D administration throughout the lifespan, as well as in select conditions (pregnancy and prediabetes). The panel defined “empiric supplementation” as vitamin D intake that (a) exceeds the Dietary Reference Intakes (DRI) and (b) is implemented without testing for 25(OH)D. Systematic reviews queried electronic databases for publications related to these 14 clinical questions. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology was used to assess the certainty of evidence and guide recommendations. The approach incorporated perspectives from a patient representative and considered patient values, costs and resources required, acceptability and feasibility, and impact on health equity of the proposed recommendations. The process to develop this clinical guideline did not use a risk assessment framework and was not designed to replace current DRI for vitamin D. Results The panel suggests empiric vitamin D supplementation for children and adolescents aged 1 to 18 years to prevent nutritional rickets and because of its potential to lower the risk of respiratory tract infections; for those aged 75 years and older because of its potential to lower the risk of mortality; for those who are pregnant because of its potential to lower the risk of preeclampsia, intra-uterine mortality, preterm birth, small-for-gestational-age birth, and neonatal mortality; and for those with high-risk prediabetes because of its potential to reduce progression to diabetes. Because the vitamin D doses in the included clinical trials varied considerably and many trial participants were allowed to continue their own vitamin D–containing supplements, the optimal doses for empiric vitamin D supplementation remain unclear for the populations considered. For nonpregnant people older than 50 years for whom vitamin D is indicated, the panel suggests supplementation via daily administration of vitamin D, rather than intermittent use of high doses. The panel suggests against empiric vitamin D supplementation above the current DRI to lower the risk of disease in healthy adults younger than 75 years. No clinical trial evidence was found to support routine screening for 25(OH)D in the general population, nor in those with obesity or dark complexion, and there was no clear evidence defining the optimal target level of 25(OH)D required for disease prevention in the populations considered; thus, the panel suggests against routine 25(OH)D testing in all populations considered. The panel judged that, in most situations, empiric vitamin D supplementation is inexpensive, feasible, acceptable to both healthy individuals and health care professionals, and has no negative effect on health equity. Conclusion The panel suggests empiric vitamin D for those aged 1 to 18 years and adults over 75 years of age, those who are pregnant, and those with high-risk prediabetes. Due to the scarcity of natural food sources rich in vitamin D, empiric supplementation can be achieved through a combination of fortified foods and supplements that contain vitamin D. Based on the absence of supportive clinical trial evidence, the panel suggests against routine 25(OH)D testing in the absence of established indications. These recommendations are not meant to replace the current DRIs for vitamin D, nor do they apply to people with established indications for vitamin D treatment or 25(OH)D testing. Further research is needed to determine optimal 25(OH)D levels for specific health benefits.
Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy
Montagna, Giacomo , Mrdutt, Mary M., Hlavin, Callie , Diego, Emilia J. , Wong, Stephanie M. , Barrio, Andrea V. , Bruele, Astrid Botty van den , Cabıoğlu, Neslihan , Sevilimedu, Varadan , Hwang, E. Shelley, Ingham, Abigail, Papassotiropoulos, Bärbel , Nguyen-Sträuli, Bich Doan , Kurzeder, Christian , Aybar, Danilo Díaz, Vorburger, Denise , Matlac, Dieter Michael, Fitzal, Florian , Meani, Francesco , Fick, Franziska, Sagasser, Jacqueline, Heil, Jörg, Dedes, Konstantin J. , Romics, László , Banys‐Paluchowski, Maggie , Müslümanoğlu, Mahmut , Pérez, María del Rosario Cueva, Díaz, Marcelo Chávez , Heidinger, Martin , Fehr, Mathias K. , Tükenmez, Mustafa , Maggi, Nadia , Ditsch, Nina , Zarhi, Sebastián Solé, Küemmel, Sherko , Bruz̆as, S., Lascio, Simona Di , Parissenti, Tamara K., Güth, Uwe , Ovalle, Valentina , Tausch, Christoph, Kuerer, Henry M. , Caudle, Abigail S. , Boileau, Jean-François , Kühn, Thorsten, Morrow, Monica , Weber, William P. , Hoskin, Tanya L. , Heidinger, Martin , Weber, Walter P , Wong, Stephanie M , Mrdutt, Mary M , Sun, Susie X. , Rosenberger, Laura H. , Matlac, Dieter Michael , Ostapenko, Edvin , Riedel, Fabian , Heil, Jörg, Karanlık, Hasan , Reinisch, Mattea , Rocco, Nicola , Gentilini, Oreste D , Paulinelli, Régis Resende , Boughey, Judy C.

JAMA Oncology | April 25, 2024 | Volume: 10 | Issue: 6 | Pages: 793

10.1001/jamaoncol.2024.0578 | PMID 38662396 Get It

ImportanceData on oncological outcomes after omission of axillary lymph node dissection (ALND) in patients with breast cancer that downstages from node positive to negative with neoadjuvant chemotherapy are sparse. Additionally, the best axillary surgical staging technique in this scenario is unknown.ObjectiveTo investigate oncological outcomes after sentinel lymph node biopsy (SLNB) with dual-tracer mapping or targeted axillary dissection (TAD), which combines SLNB with localization and retrieval of the clipped lymph node.Design, Setting, and ParticipantsIn this multicenter retrospective cohort study that was conducted at 25 centers in 11 countries, 1144 patients with consecutive stage II to III biopsy-proven node-positive breast cancer were included between April 2013 and December 2020. The cumulative incidence rates of axillary, locoregional, and any invasive (locoregional or distant) recurrence were determined by competing risk analysis.ExposureOmission of ALND after SLNB or TAD.Main Outcomes and MeasuresThe primary end points were the 3-year and 5-year rates of any axillary recurrence. Secondary end points included locoregional recurrence, any invasive (locoregional and distant) recurrence, and the number of lymph nodes removed.ResultsA total of 1144 patients (median [IQR] age, 50 [41-59] years; 78 [6.8%] Asian, 105 [9.2%] Black, 102 [8.9%] Hispanic, and 816 [71.0%] White individuals; 666 SLNB [58.2%] and 478 TAD [41.8%]) were included. A total of 1060 patients (93%) had N1 disease, 619 (54%) had ERBB2 (formerly HER2)–positive illness, and 758 (66%) had a breast pathologic complete response. TAD patients were more likely to receive nodal radiation therapy (85% vs 78%; P = .01). The clipped node was successfully retrieved in 97% of TAD cases and 86% of SLNB cases (without localization). The mean (SD) number of sentinel lymph nodes retrieved was 3 (2) vs 4 (2) (P < .001), and the mean (SD) number of total lymph nodes removed was 3.95 (1.97) vs 4.44 (2.04) (P < .001) in the TAD and SLNB groups, respectively. The 5-year rates of any axillary, locoregional, and any invasive recurrence in the entire cohort were 1.0% (95% CI, 0.49%-2.0%), 2.7% (95% CI, 1.6%-4.1%), and 10% (95% CI, 8.3%-13%), respectively. The 3-year cumulative incidence of axillary recurrence did not differ between TAD and SLNB (0.5% vs 0.8%; P = .55).Conclusions and RelevanceThe results of this cohort study showed that axillary recurrence was rare in this setting and was not significantly lower after TAD vs SLNB. These results support omission of ALND in this population.
Ciliopathy patient variants reveal organelle-specific functions for TUBB4B in axonemal microtubules
Dodd, Daniel O , Mechaussier, Sabrina , Yeyati, Patricia L. , McPhie, Fraser , Anderson, Jacob R. , Khoo, Chen Jing , Shoemark, Amelia , Gupta, Deepesh Kumar , Attard, Thomas, Zariwala, Maimoona A. , Legendre, Marie , Bracht, Diana , Gui, Miao , Parry, David , Black, Holly A. , Mitri-Frangieh, Rana, Faucon, Catherine, Kaplan, Josseline, Megaw, Roly , Mohamed, Mai A., Aitken, Stuart , Gautier, Philippe , Reinholt, Finn R., Hirst, Robert A. , O’Callaghan, Chris, Bottier, Mathieu , Escudier, Estelle , Crowley, Suzanne , Descartes, Maria , Kenia, Priti , Amiel, Jeanne , Bacci, Giacomo Maria , Calogero, Claudia , Palazzo, Viviana , Tiberi, Lucia , Blümlein, Ulrike, Rogers, Andrew, Wenger, David A. , Fulton, Anne B. , Rosenfeld, Margaret , Holm, Ingrid A., Quigley, Alan J. , Murphy, Laura C. , Cassidy, Diane M. , Kriegsheim, Alex von , Partnership, Scottish Genomes, Network, Undiagnosed Diseases, Murris, Marlène , Hogg, Claire , Macleod, Kenneth , Urquhart, Don S. , Unger, Stefan , Amselem, Serge , Leigh, Margaret W. , Knowles, Michael R. , Mitchison, Hannah M. , Rozet, Jean‐Michel , Mill, Pleasantine , Gupta, Deepesh K , Wallmeier, Julia , Fassad, Mahmoud R , Tennant, Peter A , Meynert, Alison , Wheway, Gabrielle , Fares-Taie, Lucas , Black, Holly A , Patel, Mitali , McKie, Lisa , Megaw, Roly , Aitken, Stuart , Gautier, Philippe , Heimdal, Ketil , Bottier, Mathieu , Escudier, Estelle , Crowley, Suzanne , Descartes, Maria , Jabs, Ethylin W , Bacci, Giacomo Maria , Calogero, Claudia , Tiberi, Lucia , Wambach, Jennifer A , Wegner, Daniel J , Fulton, Anne B , Kenna, Margaret , Quigley, Alan , Hall, Emma A , Murphy, Laura C , Cassidy, Diane M , von Kriegsheim, Alex , Pasquier, Laurent , Murris, Marlène S , Chalmers, James D , Hogg, Claire , Macleod, Kenneth A , Urquhart, Don S , Unger, Stefan , Aitman, Timothy J , Leigh, Margaret W , Omran, Heymut , Mitchison, Hannah M , Brown, Alan , Marsh, Joseph A , Ti, Shih-Chieh , Horani, Amjad , Rozet, Jean-Michel , Perrault, Isabelle , Mill, Pleasantine , Dodd, Daniel O. , Mechaussier, Sabrina , Gatsogiannis, Christos , Holm, Ingrid A., Partnership, Scottish Genomes, Network, Undiagnosed Diseases, Papon, Jean‐François , Pasquier, Laurent , Chalmers, James D. , Omran, Heymut , Welburn, Julie P. I.

Science | April 25, 2024 | Volume: 384 | Issue: 6694 | Pages: No page available

10.1126/science.adf5489 | PMID 38662826 Get It

Tubulin, one of the most abundant cytoskeletal building blocks, has numerous isotypes in metazoans encoded by different conserved genes. Whether these distinct isotypes form cell type– and context-specific microtubule structures is poorly understood. Based on a cohort of 12 patients with primary ciliary dyskinesia as well as mouse mutants, we identified and characterized variants in the TUBB4B isotype that specifically perturbed centriole and cilium biogenesis. Distinct TUBB4B variants differentially affected microtubule dynamics and cilia formation in a dominant-negative manner. Structure-function studies revealed that different TUBB4B variants disrupted distinct tubulin interfaces, thereby enabling stratification of patients into three classes of ciliopathic diseases. These findings show that specific tubulin isotypes have distinct and nonredundant subcellular functions and establish a link between tubulinopathies and ciliopathies.
Reliability and Responsiveness of Clinical and Endoscopic Outcome Measures in Crohn’s Disease
Khanna, Reena , Feagan, Brian G. , Stitt, Larry, McDonald, John WD, Bressler, Brian , Panaccione, Remo , Shackelton, Lisa M. , VanViegen, Tanja, Jairath, Vipul , D’Haens, Geert , Sandborn, William J. , Jairath, Vipul , Jairath, Vipul , Panaccione, Remo , D'Haens, G , Jairath, V , Jairath, V , Jairath, Vipul , Zou, Guangyong , Loftus, Edward V. , Daperno, Marco

Inflammatory Bowel Diseases | April 25, 2024 | Volume: 31 | Issue: 3 | Pages: 706-715

10.1093/ibd/izae089 | PMID 38661492 Get It

Abstract Background Regulatory guidance for Crohn’s disease trials recommends coprimary efficacy end points that evaluate both symptoms and mucosal inflammation. We aimed to characterize the operating properties of commonly used disease activity assessments alone and in combination. Methods Endoscopic and clinical data were available for 129 participants from the Study of Biologic and Immunomodulator Naïve Patients in Crohn’s Disease trial. Readers scored the Simple Endoscopic Score for Crohn’s Disease and the Crohn’s Disease Endoscopic Index of Severity using standardized conventions. Index reliability was determined using intraclass correlation coefficients. Index responsiveness was assessed using standardized effect sizes based upon treatment assignment. Outcomes were evaluated for optimal sensitivity to treatment effect. Results Substantial inter-rater reliability was observed when the Simple Endoscopic Score for Crohn’s Disease and Crohn’s Disease Endoscopic Index of Severity were used as continuous measures (intraclass correlation coefficient, 0.64; 95% confidence interval [CI], 0.50-0.73; and 0.62 95% CI, 0.36-0.77) compared with moderate reliability when dichotomized (0.46; 95% CI, 0.26-0.65; and 0.51; 95% CI, 0.00-0.78). The Simple Endoscopic Score for Crohn’s Disease, Crohn’s Disease Endoscopic Index of Severity, patient-reported outcome-2, and Crohn’s Disease Activity Index were similarly responsive (standardized effect size, 0.43, 95% CI, 0.05-0.81; 0.38, 95% CI, 0.0-0.76; 0.53, 95% CI, 0.15-0.91). A composite outcome of Crohn’s Disease Activity Index score <150 and Crohn’s Disease Endoscopic Index of Severity score <6 was most sensitive to treatment effect (28.9%; 95% CI, 11.0%-46.8%; P = .003). Conclusion Endoscopic indices were more reliable as continuous measures. Composite outcomes including endoscopy improved sensitivity to treatment effect.
Description and evaluation of a self-operated waist measurement device
Song, Yilin , Philbrick, Kenneth A. , Weston, Alexander D. , Potretzke, Theodora A. , Lytle, Kelli A. , Jensen, Teresa B. , Jensen, Michael D.

BMJ Innovations | April 25, 2024 | Volume: 10 | Issue: 3 | Pages: 88-95

10.1136/bmjinnov-2023-001162 Get It

Background National guidelines recommend that waist circumference (WC) be measured in patients with a body mass index (BMI) 27–35 kg/m2. Unfortunately, perhaps due to logistical reasons, WC is seldom measured in clinical settings. Herein, we describe the performance of a self-operated waist measurement device (SOWMD) as a potential means to overcome barriers to measuring WC. Materials and methods Ten volunteers underwent WC measures by professionals and SOWMD on 5 separate days to assess the reproducibility and accuracy. We then compared SOWMD measures with CT-derived fat content by recruiting 81 patients scheduled for a diagnostic abdominal CT scan. Results There was no difference between professionally measured and SOWMD-measured WC; the intraindividual coefficient of variation over the 5 days was between 0.4% and 2.2%. The WC measured manually, by SOWMD and CT scan were highly correlated (r=0.90–0.92, all p<0.001). The minimal WC measured by SOWMD was a better predictor (r=0.81 for all patients, r=0.87 for men, both p<0.001) of CT-measured visceral adipose tissue volume than other approaches. The minimal WC measured by SOWMD was correlated with fasting plasma glucose (r=0.40, p<0.05), triglyceride (r=0.41, p<0.01) and high-density cholesterol (r=−0.49, p<0.001) concentrations. Conclusion SOWMD is a reproducible, accurate and convenient way to measure WC that can provide added value for health care providers when combined with BMI information.
INHIBITORS OF INORGANIC POLYPHOSPHATE AND NUCLEIC ACIDS ATTENUATE IN VITRO THROMBIN GENERATION IN PLASMA FROM TRAUMA PATIENTS
Goswami, Julie , Navarro, Sergio M. , Vappala, Sreeparna , La, Chanel C. , Yudin, Nikoli , Zietlow, John , Morrissey, James H. , Spears, Grant M. , Bailey, Kent R. , Dong, Jing‐fei , Kozar, Rosemary A. , Kizhakkedathu, Jayachandran N. , Park, Myung S., MacArthur, Taleen A. , Navarro, Sergio Michael , Smith, Stephanie A.

Shock | April 25, 2024 | Volume: 61 | Issue: 6 | Pages: 848-854

10.1097/shk.0000000000002362 | PMID 38662595 Get It

ABSTRACT Background: Inorganic polyphosphate (polyP) is a procoagulant polyanion. We assessed the impact of polyP inhibition on thrombin generation after trauma using the novel polyP antagonists, macromolecular polyanion inhibitor 8 (MPI 8), and universal heparin reversal agent 8 (UHRA-8). Methods: Plasma thrombin generation (calibrated automated thrombogram, CAT), in 56 trauma patients and 39 controls +/− MPI 8 and UHRA-8 (50 μg/mL), was expressed as lag time (LT, minutes), peak height (PH, nM), and time to peak (ttPeak, minutes), with change in LT (ΔLT) and change in ttPeak (ΔttPeak) quantified. Results expressed in median and quartiles [Q1, Q3], Wilcoxon matched-pairs testing, P < 0.05 significant. Results: Trauma patients had greater baseline PH than controls (182.9 [121.0, 255.2]; 120.5 [62.1, 174.8], P < 0.001). MPI 8 treatment prolonged LT and ttPeak in trauma (7.20 [5.88, 8.75]; 6.46 [5.45, 8.93], P = 0.020; 11.28 [8.96, 13.14]; 11.00 [8.95, 12.94], P = 0.029) and controls (7.67 [6.67, 10.50]; 6.33 [5.33, 8.00], P < 0.001; 13.33 [11.67, 15.33]; 11.67 [10.33, 13.33], P < 0.001). UHRA-8 treatment prolonged LT and ttPeak and decreased PH in trauma (9.09 [7.45, 11.33]; 6.46 [5.45, 8.93]; 14.02 [11.78, 17.08]; 11.00 [8.95, 12.94]; 117.4 [74.5, 178.6]; 182.9 [121.0, 255.2]) and controls (9.83 [8.00, 12.33]; 6.33 [5.33, 8.00]; 16.67 [14.33, 20.00]; 11.67 [10.33, 13.33]; 55.3 [30.2, 95.9]; 120.5 [62.1, 174.8]), all P < 0.001. Inhibitor effects were greater for controls (greater ΔLT and ΔttPeak for both inhibitors, P < 0.001). Conclusion: PolyP inhibition attenuates thrombin generation, though to a lesser degree in trauma than in controls, suggesting that polyP contributes to accelerated thrombin generation after trauma.
Searching for Screening
Zippi, Zachary , Grage, Rolf A. , Johnson, Elizabeth , Mergo, Patricia J. , Sonavane, Sushil, Stowell, Justin T. , Sonavane, Sushil K, Little, Brent P.

Journal of Thoracic Imaging | April 25, 2024 | Volume: 39 | Issue: 6 | Pages: 342-343

10.1097/rti.0000000000000785 | PMID 38662555 Get It

A Patient with Unexpected Golden Brown Tubular Staining
Bhasin, Bhavna , Bhasin-Chhabra, Bhavna , Smith, Maxwell L.

Kidney360 | April 25, 2024 | Volume: 5 | Issue: 4 | Pages: 631-632

10.34067/kid.0000000000000366 | PMID 38662537 Get It

Trends in volumes and survival after hematopoietic cell transplantation in racial/ethnic minorities
Khera, Nandita , Brazauskas, Ruta , Patel, Jinalben , Üstün, Celalettin , Ballen, Karen K. , Abid, Muhammad Bilal , Díaz, Miguel Ángel , Al‐Homsi, A. Samer, Hong, Sanghee , Munker, Reinhold , Schears, Raquel M. , Ciurea, Stefan O. , Wirk, Baldeep , LeMaistre, Charles F. , Aljurf, Mahmoud , Sharma, Akshay , Černý, Jan , Kindwall‐Keller, Tamila L. , Winestone, Lena E. , Steinberg, Amir , Arnold, Staci D. , Seo, Sachiko , Preussler, Jaime M. , Hossain, Nasheed , Hashmi, Shahrukh K. , Lehmann, Leslie , Wood, William A. , Rangarajan, Hemalatha G. , Saber, Wael , Hahn, Theresa , Patel, Jinalben , Ustun, Celalettin , Abid, Muhammad Bilal , Diaz Perez, Miguel Angel , Hashem, Hasan , Ciurea, Stefan O , Badawy, Sherif M , Savani, Bipin N , LeMaistre, C Fred , Bhatt, Neel S , Sharma, Akshay , Cerny, Jan , Knight, Jennifer M , Kelkar, Amar H , Winestone, Lena E , Arnold, Staci D , Seo, Sachiko , Preussler, Jaime M , Hossain, Nasheed M , Fingrut, Warren B , Hashmi, Shahrukh K , Rangarajan, Hemalatha G , Wood, William A , Ailawadhi, Sikander , Jacobs, Benjamin, Hashem, Hasan , Lazarus, Hillard M. , Badawy, Sherif M. , Savani, Bipin N. , Bhatt, Neel S. , Beitinjaneh, Amer , Knight, Jennifer M. , Yared, Jean A. , Fingrut, Warren , Agrawal, Vaibhav

Blood Advances | April 25, 2024 | Volume: 8 | Issue: 13 | Pages: 3497-3506

10.1182/bloodadvances.2023012469 | PMID 38661372 Get It

Abstract There has been an increase in volume as well as an improvement in overall survival (OS) after hematopoietic cell transplantation (HCT) for hematologic disorders. It is unknown if these changes have affected racial/ethnic minorities equally. In this observational study from the Center for International Blood and Marrow Transplant Research of 79 904 autologous (auto) and 65 662 allogeneic (allo) HCTs, we examined the volume and rates of change of autoHCT and alloHCT over time and trends in OS in 4 racial/ethnic groups: non-Hispanic Whites (NHWs), non-Hispanic African Americans (NHAAs), and Hispanics across 5 2-year cohorts from 2009 to 2018. Rates of change were compared using Poisson model. Adjusted and unadjusted Cox proportional hazards models examined trends in mortality in the 4 racial/ethnic groups over 5 study time periods. The rates of increase in volume were significantly higher for Hispanics and NHAAs vs NHW for both autoHCT and alloHCT. Adjusted overall mortality after autoHCT was comparable across all racial/ethnic groups. NHAA adults (hazard ratio [HR] 1.13; 95% confidence interval [CI] 1.04-1.22; P = .004) and pediatric patients (HR 1.62; 95% CI 1.3-2.03; P &lt; .001) had a higher risk of mortality after alloHCT than NHWs. Improvement in OS over time was seen in all 4 groups after both autoHCT and alloHCT. Our study shows the rate of change for the use of autoHCT and alloHCT is higher in NHAAs and Hispanics than in NHWs. Survival after autoHCT and alloHCT improved over time; however, NHAAs have worse OS after alloHCT, which has persisted. Continued efforts are needed to mitigate disparities for patients requiring alloHCT.
Transforming the oncology data paradigm by creating, capturing, and retrieving structured cancer data at the point of care: A Mayo Clinic pilot
Tevaarwerk, Amyé , Karam, Dhauna , Gatten, Clare A., Harlos, Elizabeth S., Maurer, Matthew J. , Haddad, Tufia C. , Stockham, Abigail L. , Leventakos, Konstantinos , Chen, Ruqin , Jochum, Jacob A., Schwecke, Anna, Eiring, Rachel A. , Carroll, Jamie L., Mandrekar, Sumithra J. , Tevaarwerk, Amye J , Holton, Sara J, Stockham, Abigail, Hubbard, Joleen M. , Mansfield, Aaron S , Halfdanarson, Thorvardur R , Schwecke, Anna S, Riaz, Irbaz Bin , McWilliams, Robert R , Galanis, Evanthia , Maurer, Matthew , Eiring, Rachel A , Giridhar, Karthik V. , Alberts, Steven R. , Holton, Sara J., Mansfield, Aaron S. , Hálfdánarson, Þorvarður R. , Carroll, Jamie M. , McWilliams, Robert R. , Galanis, Evanthia

Cancer | April 25, 2024 | Volume: 131 | Issue: 1 | Pages: No page available

10.1002/cncr.35304 | PMID 38662502 Get It

AbstractIntroductionStructured data capture requires defined languages such as minimal Common Oncology Data Elements (mCODE). This pilot assessed the feasibility of capturing 5 mCODE categories (stage, disease status, performance status (PS), intent of therapy and intent to change therapy).MethodsA tool (SmartPhrase) using existing and custom structured data elements was Built to capture 4 data categories (disease status, PS, intent of therapy and intent to change therapy) typically documented as free‐text within notes. Existing functionality for stage was supported by the Build. Participant survey data, presence of data (per encounter), and time in chart were collected prior to go‐live and repeat timepoints. The anticipated outcome was capture of >50% sustained over time without undue burden.ResultsPre‐intervention (5‐weeks before go‐live), participants had 1390 encounters (1207 patients). The median percent capture across all participants was 32% for stage; no structured data was available for other categories pre‐intervention. During a 6‐month pilot with 14 participants across three sites, 4995 encounters (3071 patients) occurred. The median percent capture across all participants and all post‐intervention months increased to 64% for stage and 81%–82% for the other data categories post‐intervention. No increase in participant time in chart was noted. Participants reported that data were meaningful to capture.ConclusionsStructured data can be captured (1) in real‐time, (2) sustained over time without (3) undue provider burden using note‐based tools. Our system is expanding the pilot, with integration of these data into clinical decision support, practice dashboards and potential for clinical trial matching.